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http://dx.doi.org/10.1016/j.jare.2013.07.002As reported by Rashida Barakat in ‘‘Epidemiology of
Schistosomiasis in Egypt-Travel through Time’’ Schistosoma
haematobium was endemic in Ancient Egypt, and although
successful control projects have been implemented in the last
50 years, yet neither the number of endemic countries nor
the estimated number of people infected or at risk of infection
were reduced’’. Accordingly, nothing could be more irritating
and dangerous than the continuous assertions of authorities
in the Egyptian Ministry of Health and Population (MOHP)
that schistosomiasis is near elimination in Egypt. This is irritat-
ing because it is untrue. The assertion is based on analyses of
stool or urine, while modern and more accurate techniques are
entirely unavailable. Indeed, it is said that 207 million people
worldwide are now reported to be infected with schistosomes,
while researchers argue that this number is a very gross under-
estimate because of the limited sensitivity of diagnostic tech-
niques, leading to about 40–60% missed diagnoses.
Spreading the word that schistosomiasis is disappearing from
Egypt discourages vigilance and compliance to treatment,
and leads to increase in number of persons unaware of their
infection until death by hematemesis or superinfection with he-
patic viruses with all the sequelae. People with insidious schis-
tosomiasis are unable to combat viral infections, and are thus
harmed and represent a reservoir for infection of the commu-
nity. A circumstantial evidence is the superimposition of areas
of higher prevalence of hepatitis C virus and regions where
schistosomiasis prevails, i.e. the rural areas. This nonstop
assertion that schistosomiasis is now a trivial problem in Egypt
discourages scientists from developing and implementing accu-
rate diagnostic techniques, alternative drugs, and most impor-
tantly vaccines in an aim to truly eradicate this infection not
only from Egypt but from the face of the world. Accordingly,
this Special Issue on several aspects of schistosomiasis is most
timely and precious, reviving the knowledge and interest in this
infection, now relegated by the scientiﬁc community, including
the World Health Organization, to the status of a neglected
tropical disease.
The studies reported and discussed by Rashida Barakat in
the ﬁrst Review of this special issue indicate the great successof the Egyptian MOHP in decreasing the prevalence of schis-
tosomiasis mansoni and haematobium from 60% in the years
1930 and 1940 to 3% or less nowadays. However, the last epi-
demiological studies were performed in 2000, and there are no
more recent deﬁnite established epidemiological studies. The
mass use of praziquantel may have led to changes in the biol-
ogy of schistosomes perhaps eliciting lower inability of the eggs
to exit the human body with consequent inability of detection,
and higher amount of eggs lodging in the tissues while
unawareness of this dangerous situation is the rule. Accord-
ingly, it is recommended that a national epidemiological study
is implemented without delay, provided that modern and accu-
rate immunological and molecular biology diagnostic tools are
used beside the Kato-Katz technique.
This issue includes 3 comprehensive and integrated reviews
on the clinical aspects of schistosomiasis caused by Schisto-
soma mansoni and Schistosoma haematobium by expert leaders
who have managed and treated thousands of human cases. The
review by Rashad S. Barsoum, Gamal Esmat and Tamer El-
Baz, establishes the foundation and documents the concept
of a novel perspective for clinical schistosomiasis, whereby
clinical manifestations of the disease, the acute, sub-acute
and chronic stages, mirror the progression of the host’s im-
mune responses to the process of parasite’s maturation. In
addition to the full, well-illustrated, description of the clinical
aspects of schistosomiasis involving primary and secondary
targets, the authors elaborate on the major sequelae, namely
amyloidosis, malignancy, and bacterial and viral co-infections,
and provide the advice of experts for the management and
treatment of the disease. In the review ‘‘Hepatic and Intestinal
Schistosomiasis’’ by Tamer ElBaz and Gamal Esmat, the dis-
ease caused by S. mansoni is not named hepato-intestinal schis-
tosomiasis, as the authors explain that intestinal
schistosomiasis represents a form different from hepatic schis-
tosomiasis, and report on the differences in pathogenesis and
clinical manifestation. The authors then discuss their experi-
ence with diagnostic techniques and schistosomicidal drugs,
and recommend development of an effective vaccine for pre-
vention of the infection and elimination of transmission. In
the Review ‘‘Urinary Schistosomiasis’’ by Rashad Barsoum,
the clinical manifestations of the disease are displayed from
a pathogenetic perspective, and categorized as cellular immu-
nity- and immune complex-mediated disorders. The inﬂamma-
tory and ﬁbrotic lesions in the different parts of the urinary
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manner. The author then elaborates, in depth, on the immune-
complex-related six clinicopathological classes mostly associ-
ated with S. mansoni, and on Schistosoma associated bacterial
and viral infections, and bladder neoplasia.
The issue of ‘‘Schistosomiasis and Cancer in Egypt’’ is dealt
by Hussein M. Khaled who reviewed the epidemiology, etiol-
ogy, biological aspects, and clinic-pathologic characteristics
of bladder cancer and explained in depth its changing patterns
in Egypt, and how these changes affect treatment and manage-
ment. The author shares his experience and expertise regarding
options of radiotherapy and chemotherapy alone or in combi-
nation, and recommends gemcitabine-cisplatin regimens for
the patients, provided they still have remnants of vigor and ﬁt-
ness. It is obvious that long-term survival rates of patients with
invasive disease which range between 30%-50% are largely
unsatisfactory. This should enhance efforts for preventionand detection of bladder tumors at early disease stages. This
would entail more media campaigns and more close collabora-
tion with health care authorities in the concerned countries.
Enhanced vaccine development comes undoubtedly on top of
the list of these efforts.
It is miraculous that Rashika El Ridi and Hatem Tallima
were able in the midst of all this frustration to relentlessly carry
on research on the biology of the lung-stage schistosomula, the
documented target of innate and acquired immunity against
invading schistosomes, as shown in the last review of this Spe-
cial Issue. Elucidating the basis of immune evasion in this stage
and in adult worms paved the way to development of arachi-
donic acid as a remedy for schistosomiasis as it is schistosomi-
cidal and an essential nutrient as well. Additionally, proper
selection of candidate vaccine antigens and the correct adju-
vant led them to open novel avenues for development of an
efﬁcacious schistosomiasis vaccine.
